Synergy Pharmaceuticals (FRA:S90) Debt-to-Equity : -1.24 (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Debt-to-Equity?

Synergy Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was €102.47 Mil. Synergy Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was €0.00 Mil. Synergy Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2018 was €-82.48 Mil. Synergy Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2018 was -1.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Synergy Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:S90' s Debt-to-Equity Range Over the Past 10 Years
Min: -67.77 Med: -1.82 Max: 6.31
Current: -1.24

During the past 12 years, the highest Debt-to-Equity Ratio of Synergy Pharmaceuticals was 6.31. The lowest was -67.77. And the median was -1.82.

FRA:S90's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs FRA:S90: -1.24

Synergy Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Synergy Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Debt-to-Equity Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Debt-to-Equity

Get a 7-Day Free Trial

-36.38

-2.74

0.60

-21.01

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Debt-to-Equity	Get a 7-Day Free Trial															-67.78	-21.01	-3.01	-1.82	-1.24

Competitive Comparison of Synergy Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synergy Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Debt-to-Equity falls into.

Synergy Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Synergy Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	97.988)	/	-4.663
	=	-21.01

Synergy Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2018 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(102.474	+	0)	/	-82.481
	=	-1.24

Synergy Pharmaceuticals (FRA:S90) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Synergy Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines